Cargando…

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma

Recently, combination regimens based on programmed cell death-1 (PD-1) blockade have become increasingly common in clinical practice for the treatment of cancer. Such combinations significantly improve efficacy, but treatment-related adverse events have also become more complex and severe. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yonghao, Li, Jun, Till, Brian G., Wang, Jun, Zhang, Bicheng, Wang, Hanping, Huang, Hao, Li, Tiepeng, Gao, Quanli, Li, Hongle, Wang, Zibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586206/
https://www.ncbi.nlm.nih.gov/pubmed/34778042
http://dx.doi.org/10.3389/fonc.2021.728253
_version_ 1784597845943255040
author Yang, Yonghao
Li, Jun
Till, Brian G.
Wang, Jun
Zhang, Bicheng
Wang, Hanping
Huang, Hao
Li, Tiepeng
Gao, Quanli
Li, Hongle
Wang, Zibing
author_facet Yang, Yonghao
Li, Jun
Till, Brian G.
Wang, Jun
Zhang, Bicheng
Wang, Hanping
Huang, Hao
Li, Tiepeng
Gao, Quanli
Li, Hongle
Wang, Zibing
author_sort Yang, Yonghao
collection PubMed
description Recently, combination regimens based on programmed cell death-1 (PD-1) blockade have become increasingly common in clinical practice for the treatment of cancer. Such combinations significantly improve efficacy, but treatment-related adverse events have also become more complex and severe. Here, we report an acute toxic epidermal necrolysis (TEN)-like reaction in a patient with gallbladder cancer who received camrelizumab (an anti-PD-1 antibody) in combination with apatinib. Interestingly, distinct clinical and pathological characteristics were observed that differed from those of the reported cases of severe cutaneous reactions induced by anti-PD-1 antibodies alone; thus, we speculate that it was induced by the combination of camrelizumab and apatinib. It is worth noting that the TEN-like reaction showed resistance to methylprednisolone initially, which was gradually resolved after the addition of intravenous immunoglobulin (IVIg). Immunohistochemical staining revealed that the skin lesion was infiltrated by moderate numbers of CD4+ T cells and large numbers of CD8+ T cells during the progression of the TEN-like reaction, and mass cytometry by time-of-flight showed a significant reduction in the CD4+ and CD8+ T cell proportions in the peripheral blood after the rash improved. All these findings highlight the essential role of CD4+ T cells and CD8+ T cells in the TEN-like reaction induced by camrelizumab plus apatinib treatment, and we speculate that T cells, especially CD8+ T cells, attack keratinocytes. In conclusion, the TEN-like reaction induced by camrelizumab and apatinib deserves clinical attention, and further work is needed to elucidate the exact pathophysiologic mechanism as well as the optimal management strategy.
format Online
Article
Text
id pubmed-8586206
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85862062021-11-13 Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma Yang, Yonghao Li, Jun Till, Brian G. Wang, Jun Zhang, Bicheng Wang, Hanping Huang, Hao Li, Tiepeng Gao, Quanli Li, Hongle Wang, Zibing Front Oncol Oncology Recently, combination regimens based on programmed cell death-1 (PD-1) blockade have become increasingly common in clinical practice for the treatment of cancer. Such combinations significantly improve efficacy, but treatment-related adverse events have also become more complex and severe. Here, we report an acute toxic epidermal necrolysis (TEN)-like reaction in a patient with gallbladder cancer who received camrelizumab (an anti-PD-1 antibody) in combination with apatinib. Interestingly, distinct clinical and pathological characteristics were observed that differed from those of the reported cases of severe cutaneous reactions induced by anti-PD-1 antibodies alone; thus, we speculate that it was induced by the combination of camrelizumab and apatinib. It is worth noting that the TEN-like reaction showed resistance to methylprednisolone initially, which was gradually resolved after the addition of intravenous immunoglobulin (IVIg). Immunohistochemical staining revealed that the skin lesion was infiltrated by moderate numbers of CD4+ T cells and large numbers of CD8+ T cells during the progression of the TEN-like reaction, and mass cytometry by time-of-flight showed a significant reduction in the CD4+ and CD8+ T cell proportions in the peripheral blood after the rash improved. All these findings highlight the essential role of CD4+ T cells and CD8+ T cells in the TEN-like reaction induced by camrelizumab plus apatinib treatment, and we speculate that T cells, especially CD8+ T cells, attack keratinocytes. In conclusion, the TEN-like reaction induced by camrelizumab and apatinib deserves clinical attention, and further work is needed to elucidate the exact pathophysiologic mechanism as well as the optimal management strategy. Frontiers Media S.A. 2021-10-29 /pmc/articles/PMC8586206/ /pubmed/34778042 http://dx.doi.org/10.3389/fonc.2021.728253 Text en Copyright © 2021 Yang, Li, Till, Wang, Zhang, Wang, Huang, Li, Gao, Li and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Yonghao
Li, Jun
Till, Brian G.
Wang, Jun
Zhang, Bicheng
Wang, Hanping
Huang, Hao
Li, Tiepeng
Gao, Quanli
Li, Hongle
Wang, Zibing
Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title_full Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title_fullStr Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title_full_unstemmed Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title_short Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
title_sort toxic epidermal necrolysis-like reaction following combination therapy with camrelizumab and apatinib for advanced gallbladder carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586206/
https://www.ncbi.nlm.nih.gov/pubmed/34778042
http://dx.doi.org/10.3389/fonc.2021.728253
work_keys_str_mv AT yangyonghao toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT lijun toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT tillbriang toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT wangjun toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT zhangbicheng toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT wanghanping toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT huanghao toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT litiepeng toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT gaoquanli toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT lihongle toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma
AT wangzibing toxicepidermalnecrolysislikereactionfollowingcombinationtherapywithcamrelizumabandapatinibforadvancedgallbladdercarcinoma